JP2008546791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008546791A5 JP2008546791A5 JP2008518350A JP2008518350A JP2008546791A5 JP 2008546791 A5 JP2008546791 A5 JP 2008546791A5 JP 2008518350 A JP2008518350 A JP 2008518350A JP 2008518350 A JP2008518350 A JP 2008518350A JP 2008546791 A5 JP2008546791 A5 JP 2008546791A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- methyl
- halo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, hydroxy Chemical group 0.000 claims 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- 208000036119 Frailty Diseases 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- 206010049088 Osteopenia Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 206010003549 asthenia Diseases 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002710 gonadal effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- HQCNDGFHYHHGGO-GOSISDBHSA-N n-[(3r)-6-(methoxyiminomethyl)-9-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydrocarbazol-3-yl]cyclopropanecarboxamide Chemical compound C([C@@H](CCC=12)NC(=O)C3CC3)C=1C1=CC(C=NOC)=CC=C1N2CC1=CC=CC=N1 HQCNDGFHYHHGGO-GOSISDBHSA-N 0.000 claims 1
- FTPCLTKRSBYWCA-IBGZPJMESA-N n-[(3s)-6-cyano-9-[(3-fluorophenyl)methyl]-1,2,3,4-tetrahydrocarbazol-3-yl]-2-methylpropanamide Chemical compound C([C@@H](C1)NC(=O)C(C)C)CC2=C1C1=CC(C#N)=CC=C1N2CC1=CC=CC(F)=C1 FTPCLTKRSBYWCA-IBGZPJMESA-N 0.000 claims 1
- WIUNAUKEVPPYJI-UHFFFAOYSA-N n-[6-cyano-9-[(6-fluoropyridin-2-yl)methyl]-1,2,3,4-tetrahydrocarbazol-3-yl]cyclopropanecarboxamide Chemical compound FC1=CC=CC(CN2C3=CC=C(C=C3C=3CC(CCC=32)NC(=O)C2CC2)C#N)=N1 WIUNAUKEVPPYJI-UHFFFAOYSA-N 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69360405P | 2005-06-24 | 2005-06-24 | |
| US60/693,604 | 2005-06-24 | ||
| PCT/US2006/024122 WO2007002181A2 (en) | 2005-06-24 | 2006-06-21 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008546791A JP2008546791A (ja) | 2008-12-25 |
| JP2008546791A5 true JP2008546791A5 (https=) | 2009-08-20 |
| JP5204650B2 JP5204650B2 (ja) | 2013-06-05 |
Family
ID=37315277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008518350A Expired - Fee Related JP5204650B2 (ja) | 2005-06-24 | 2006-06-21 | アンドロゲン受容体調節物質として有用なテトラヒドロカルバゾール誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7935722B2 (https=) |
| EP (1) | EP1902026B1 (https=) |
| JP (1) | JP5204650B2 (https=) |
| CN (1) | CN101203491A (https=) |
| AT (1) | ATE457979T1 (https=) |
| AU (1) | AU2006262283B2 (https=) |
| BR (1) | BRPI0611705A2 (https=) |
| CA (1) | CA2612723A1 (https=) |
| CY (1) | CY1110014T1 (https=) |
| DE (1) | DE602006012322D1 (https=) |
| DK (1) | DK1902026T3 (https=) |
| ES (1) | ES2339480T3 (https=) |
| MX (1) | MX2007015905A (https=) |
| PL (1) | PL1902026T3 (https=) |
| PT (1) | PT1902026E (https=) |
| SI (1) | SI1902026T1 (https=) |
| WO (1) | WO2007002181A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA98777C2 (en) | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
| PL2205603T3 (pl) | 2007-09-28 | 2014-07-31 | Cyclacel Ltd | Pochodne pirymidyny jako inhibitory kinaz białkowych |
| CA2716320C (en) | 2008-02-22 | 2014-01-28 | Radius Health, Inc. | Selective androgen receptor modulators |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| EA019713B1 (ru) * | 2008-05-16 | 2014-05-30 | Эли Лилли Энд Компани | ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ |
| CN101648933B (zh) * | 2009-09-21 | 2011-07-20 | 四川大学 | 3,4-二氢-4-氧-2h-1-苯并吡喃曼尼希碱类化合物、其制备方法和用途 |
| AR078862A1 (es) | 2009-11-13 | 2011-12-07 | Lilly Co Eli | Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia |
| PL2516433T3 (pl) | 2009-12-21 | 2014-10-31 | Array Biopharma Inc | Podstawione związki N-(1H-indazol-4-ilo)imidazo[1,2-a]pirydyno-3-karboksyamidowe jako inhibitory cFMS |
| AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
| HUE030072T2 (en) | 2010-05-12 | 2017-04-28 | Radius Health Inc | Therapeutic prescriptions |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2012152741A1 (de) | 2011-05-10 | 2012-11-15 | Bayer Intellectual Property Gmbh | Bicyclische (thio)carbonylamidine |
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
| CN103694142A (zh) * | 2013-11-28 | 2014-04-02 | 浙江科技学院 | 4-N-Boc-氨基环己酮的制备方法 |
| US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
| CN106715426A (zh) | 2014-03-21 | 2017-05-24 | 拜耳医药股份有限公司 | 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途 |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| EP3227287B1 (de) | 2014-12-02 | 2019-08-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
| MX389702B (es) | 2016-06-22 | 2025-03-20 | Ellipses Pharma Ltd | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). |
| JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形性形態 |
| CN109700798A (zh) * | 2017-03-01 | 2019-05-03 | 浙江大学 | 苯并吡喃黄酮结构类型雄激素受体拮抗剂及其应用 |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| MX2020013713A (es) | 2018-07-04 | 2021-03-02 | Radius Pharmaceuticals Inc | Formas polimorficas de rad1901-2hcl. |
| EP3924328A1 (en) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| WO2024229221A1 (en) * | 2023-05-03 | 2024-11-07 | Capulus Therapeutics, Llc | Androgen receptor modulators and methods for their use |
| CN118993985A (zh) * | 2023-05-17 | 2024-11-22 | 中国医学科学院药物研究所 | 一种具有抗肿瘤活性的化合物，其制备方法及制药用途 |
| CN119874601B (zh) * | 2025-01-06 | 2025-10-31 | 山东大学 | 一种3,3-二甲基-1,2,3,4-四氢-9h-咔唑类衍生物及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959309A (en) * | 1968-01-24 | 1976-05-25 | Sterling Drug Inc. | 3-Amido-1,2,3,4-tetrahydrocarbazoles |
| US4988820A (en) * | 1986-02-21 | 1991-01-29 | Bayer Aktiengesellschaft | Cycloalkano(1,2-B) indole-sulponamides |
| GB8924392D0 (en) * | 1989-10-30 | 1989-12-20 | Bayer Ag | Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides |
| GB9008108D0 (en) * | 1990-04-10 | 1990-06-06 | Bayer Ag | Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles |
| DE4027278A1 (de) * | 1990-08-29 | 1992-03-05 | Bayer Ag | Heterocyclisch substituierte indolsulfonamide |
| GB9310635D0 (en) * | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| DE10164564B4 (de) * | 2001-12-14 | 2007-05-16 | Zentaris Gmbh | Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR) |
| WO2003051837A2 (de) * | 2001-12-14 | 2003-06-26 | Zentaris Gmbh | Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr) |
| AU2003231509A1 (en) * | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| UA79504C2 (en) * | 2002-11-07 | 2007-06-25 | Organon Nv | Indols for treating diseases associated with androgen receptors |
| WO2005004869A1 (en) * | 2003-07-07 | 2005-01-20 | Boehringer Ingelheim International Gmbh | Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| WO2006058088A2 (en) | 2004-11-23 | 2006-06-01 | Ptc Therapeutics, Inc. | Carbazole, carboline and indole derivatives useful in the inhibition of vegf production |
-
2006
- 2006-06-21 CA CA002612723A patent/CA2612723A1/en not_active Abandoned
- 2006-06-21 AU AU2006262283A patent/AU2006262283B2/en not_active Ceased
- 2006-06-21 ES ES06785258T patent/ES2339480T3/es active Active
- 2006-06-21 DE DE602006012322T patent/DE602006012322D1/de active Active
- 2006-06-21 PT PT06785258T patent/PT1902026E/pt unknown
- 2006-06-21 WO PCT/US2006/024122 patent/WO2007002181A2/en not_active Ceased
- 2006-06-21 AT AT06785258T patent/ATE457979T1/de active
- 2006-06-21 PL PL06785258T patent/PL1902026T3/pl unknown
- 2006-06-21 BR BRPI0611705A patent/BRPI0611705A2/pt not_active IP Right Cessation
- 2006-06-21 SI SI200630646T patent/SI1902026T1/sl unknown
- 2006-06-21 US US11/917,398 patent/US7935722B2/en not_active Expired - Fee Related
- 2006-06-21 JP JP2008518350A patent/JP5204650B2/ja not_active Expired - Fee Related
- 2006-06-21 MX MX2007015905A patent/MX2007015905A/es active IP Right Grant
- 2006-06-21 DK DK06785258.2T patent/DK1902026T3/da active
- 2006-06-21 CN CNA200680022629XA patent/CN101203491A/zh active Pending
- 2006-06-21 EP EP06785258A patent/EP1902026B1/en not_active Not-in-force
-
2010
- 2010-04-16 CY CY20101100347T patent/CY1110014T1/el unknown